Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Universal LCAR-BCX cell therapy - Nanjing Legend Biotech

Drug Profile

Universal LCAR-BCX cell therapy - Nanjing Legend Biotech

Alternative Names: LCAR-BCX CAR cell therapy - Nanjing Legend Biotech; LCAR-BCX cells product - Nanjing Legend Biotech

Latest Information Update: 28 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nanjing Legend Biotech
  • Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Multiple myeloma

Most Recent Events

  • 28 Nov 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in China (IV, Infusion)
  • 26 Oct 2020 Universal LCAR-BCX cell therapy - Nanjing Legend Biotech is available for licensing as of 02 Nov 2020. https://www.legendbiotech.com/about.php#partnerships (Nanjing Legend Biotech Website, November 2020)
  • 09 Oct 2020 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in China (IV) (NCT04601935)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top